Study of the CDK4/6 Inhibitor Abemaciclib in Solid Tumors Harboring Genetic Alterations in Genes Encoding D-Type Cyclins or Amplification of CDK4 or CDK6
Clinical trial NCT03310879 · RECRUITING
Trial details
- NCT number
- NCT03310879
- Sponsor
- Dana-Farber Cancer Institute
- Status
- RECRUITING
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2017-11-21
- Primary completion
- 2027-01-01
- Enrollment
- 38
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.